Radiolabeled compounds targeting the prostate-specific membrane antigen
US-2024018110-A1 · Jan 18, 2024 · US
US9085529B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9085529-B2 |
| Application number | US-201113818576-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 22, 2011 |
| Priority date | Aug 23, 2010 |
| Publication date | Jul 21, 2015 |
| Grant date | Jul 21, 2015 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention relates to a new process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a -amino- -biphenyl- -methylalkanoic acid, or acid ester, backbone, such as N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester or salt thereof.
Opening claim text (preview).
The invention claimed is: 1. A process for preparing a compound of formula (2), or salt thereof, wherein R1 and R2 are, independently of each other, hydrogen or a nitrogen protecting group, and R3 is a carboxyl group or an ester group —COOR, wherein R is C 1 -C 6 -alkyl residue, comprising the steps of A) a) reacting a compound of formula (1), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group; with a transition metal catalyst, optionally in the presence of a base, to obtain the compound of formula (4), or salt thereof wherein R1 is hydrogen or a nitrogen protecting group; or A) b) i) reacting a compound of formula (3), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group; with a selenide in the presence of a base, to obtain a compound of formula (6), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group; and R is aryl; and A) b) ii) treating the compound of formula (6) with an oxidizing agent; to obtain the compound of formula (4) or a salt thereof, and B) reacting the obtained compound of formula (4) or a salt thereof with a lactam ring opening agent to obtain a compound of formula (5) with (Z) configuration or salt thereof, wherein R1 and R2 are, independently of each other, hydrogen or a nitrogen protecting group, and R is hydrogen or a C 1 -C 6 -alkyl residue, and C) reducing the obtained compound of formula (5), or a salt thereof, to obtain the compound of formula (2). 2. A process according to claim 1 wherein the transition metal catalyst in step A) a) comprises Palladium (Pd). 3. A process according to claim 1 , wherein the reduction reaction in step C) is carried out with hydrogen in the presence of a transition metal catalyst that comprises an organometallic complex and a chiral ligand or which is an organometallic catalyst. 4. A process according to claim 3 , wherein the transition metal catalyst comprises (i) an organometallic complex and a chiral ligand, wherein a) the organometallic complex is the rhodium organometallic complex [Rh(cod) 2 ]O 3 SCF 3 or [Rh(nbd) 2 ]BF 4 and the chiral ligand is SL-A101-2, SL-A109-2, SL-A241-1, (R,R)-MOD-DIOP, (R)-PhanePhos, SL-F356-1, SL-J003-1, SL-J005-2, SL-J216-1, SL-J302-1, SL-M001-1, SL-M002-2, SL-M003-1, SL-T001-1, SL-T002-1 or SL-W008-1; b) the organometallic complex is the ruthenium organometallic complex [Ru(cod)(OOCCF 3 ) 2 ] and the chiral ligand is (R)-PhanePhos or SL-M002-2; c) the organometallic complex is a rhodium organometallic complex and the chiral ligand is SL-A242-1; or d) the organometallic complex is a ruthenium organometallic complex, and the chiral ligand is SL-A242-1 or (R,R)-BDPP; or (ii) an organometallic catalyst selected from the group consisting of [Rh(cod)(SL-P005-1)]BF 4 , [Rh(cod)(SL-P114-1)]BF 4 , and [Rh(cod)(SL-P102-1)]O 3 SCF 3 . 5. A process according to claim 1 , further comprising the step of reacting the obtained compound of formula (2), or salt thereof, wherein R1 and R2 are, independently of each other, hydrogen or a nitrogen protecting group, and R3 is a carboxyl group or an ester group —COOR, wherein R is C 1 -C 6 -alkyl residue, preferably a carboxyl group, to obtain N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester or a salt thereof, or N-(3-carboxy-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid or a salt thereof.
the carbon skeleton containing six-membered aromatic rings · CPC title
to carbon atoms of hydrocarbon radicals substituted by carboxyl groups · CPC title
Oxygen or sulfur atoms · CPC title
from lactams, cyclic ketones or cyclic oximes, e.g. by reactions involving Beckmann rearrangement · CPC title
by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.